CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Zevra Therapeutics Q3 revenue rises 45% on MIPLYFFA sales

By Reuters News


Overview

  • U.S. rare disease drugmaker's Q3 revenue rose 45% yr/yr, beating analyst expectations

  • Company posted net income in Q3, reversing a loss from a year earlier

  • Company ended Q3 with $270.9 mln in cash, supporting pipeline and commercial efforts


Outlook

  • Company awaiting outcome of EU re-examination for arimoclomol marketing authorization

  • Zevra expects to file sNDA for MIPLYFFA in infants under 24 months in Q1 2027

  • Company says current financial resources are sufficient to support strategic priorities


Result Drivers

  • MIPLYFFA SALES - Co said Q3 revenue growth was driven by sales of MIPLYFFA for Niemann-Pick disease type C

  • OPERATIONAL EXECUTION - Co attributed strong cash position to operational execution

  • PIPELINE INVESTMENT - Increased R&D spending driven by investment in arimoclomol and celiprolol development


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$37.76 mln

$37.08 mln (9 Analysts)

Q3 Net Income

$19.21 mln

Q3 Income from Operations

$11.58 mln

Q3 Operating Expenses

-$24.07 mln

Q3 Pretax Profit

$19.72 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Zevra Therapeutics, Inc. is $24.50, about 142.6% above its November 2 closing price of $10.10

  • The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 11 three months ago


Reuters Recommended Reads

  • Nov 2 - Syndax Pharmaceuticals Q3 revenue rises 82% on cancer drug sales

  • Nov 2 - BioMarin Q3 revenue rises on Amicus acquisition, adjusted EPS beats

  • Nov 2 - Neurocrine Biosciences Q3 revenue jumps 41% on strong INGREZZA, CRENESSITY, VYKAT XR demand


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.